Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and epilepsy, will be presented at the 73 rd Annual Meeting of the American Academy of Neurology (AAN), taking place virtually from April 17-22, 2021.